A recent article in Forbes examined the threat AMR poses to people with cancer and highlighted research from the Cancer and AMR Consortium on the topic, noting the AMR Action Fund’s role in establishing the Consortium, in collaboration with the Union for International Cancer Control and BD.
The article featured several experts discussing the need for new antibiotics and rapid diagnostics to better treat bacterial infections in vulnerable patient populations.
Yehoda Martei, an oncologist and assistant professor of medicine at the Hospital of the University of Pennsylvania, described this phenomenon as an example of the damaging silos that often exist in medicine. “Oncologists send blood samples to be cultured all the time, and see patients infected with multiple AMR organisms, so the issue is very apparent on an individual patient level,” she says. “What’s missing is a global acknowledgement that a crisis of AMR is a crisis of cancer care delivery.”
Read the full article here.
